Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 10.94M | 9.04M | 14.02M | 0.00 | 0.00 | 0.00 |
Gross Profit | 10.94M | 9.04M | 14.02M | -631.00K | -755.00K | -755.00K |
EBITDA | -175.18M | -151.35M | -28.00M | -36.27M | -23.95M | -17.04M |
Net Income | -205.11M | -292.96M | -106.81M | -37.51M | -24.47M | -17.12M |
Balance Sheet | ||||||
Total Assets | 342.69M | 240.24M | 148.54M | 24.05M | 57.92M | 44.52M |
Cash, Cash Equivalents and Short-Term Investments | 317.32M | 217.30M | 138.14M | 20.32M | 49.23M | 39.77M |
Total Debt | 4.77M | 4.83M | 1.65M | 293.00K | 317.00K | 613.00K |
Total Liabilities | 35.57M | 59.08M | 28.66M | 7.39M | 9.74M | 3.18M |
Stockholders Equity | 307.13M | 181.16M | 119.88M | 16.65M | 48.19M | 41.34M |
Cash Flow | ||||||
Free Cash Flow | -161.60M | -117.97M | -8.40M | -28.94M | -18.30M | -12.72M |
Operating Cash Flow | -152.68M | -110.79M | -7.57M | -28.69M | -18.23M | -12.13M |
Investing Cash Flow | -42.74M | -85.06M | -30.48M | -248.00K | -79.00K | -586.00K |
Financing Cash Flow | 183.31M | 240.53M | 116.41M | 32.00K | 27.77M | 49.94M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | $721.10M | ― | -6.33% | ― | 23.92% | -27.69% | |
55 Neutral | $708.91M | ― | -55.12% | ― | ― | -60.26% | |
51 Neutral | $346.38M | ― | -23.46% | ― | 54.55% | 36.41% | |
50 Neutral | $769.19M | ― | -69.21% | ― | -13.76% | 57.73% | |
46 Neutral | $606.22M | ― | -28.73% | ― | 189.31% | 51.03% | |
46 Neutral | C$194.71M | -4.33 | -8.58% | 2.64% | 13.66% | -0.73% | |
45 Neutral | $595.59M | ― | -150.50% | ― | ― | -18.75% |
Immunome, Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025, where stockholders elected Isaac Barchas and Jean-Jacques Bienaimé as Class II Directors to serve until the 2028 Annual Meeting. Additionally, stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (IMNM) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Immunome stock, see the IMNM Stock Forecast page.
On May 8, 2025, Immunome‘s Board of Directors approved an amendment to increase the number of shares reserved under its 2024 Inducement Plan, aimed at attracting new employees. The company reported its first-quarter 2025 financial results, highlighting a net loss of $41.6 million and a cash position expected to fund operations into 2027. Immunome is progressing with its clinical trials, including the Phase 3 RINGSIDE trial for varegacestat and Phase 1 trials for IM-1021 and IM-3050, positioning itself as a leader in targeted cancer therapies.
The most recent analyst rating on (IMNM) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Immunome stock, see the IMNM Stock Forecast page.